Adult Dosing
Acute bacterial skin and skin structure infections (ABSSSI)
- Recommended dose: single 1200 mg dose infused intravenously over 3 hrs
Note:
- Refer package insert for preparation and administration procedures
Pediatric Dosing
- Safety and effectiveness in pediatric patients has not been established
[Outline]
- Coadministration with warfarin may increase the risk of bleeding. Use oritavancin in patients on chronic warfarin therapy only when the benefits outweigh the risk of bleeding. Monitor for signs of bleeding
- Monitoring of anticoagulation effect of warfarin is unreliable for up to 12 hr after oritavancin dose because oritavancin artificially prolongs PT and INR for up to 12 hr by binding to and preventing action of the phospholipid reagents commonly used in laboratory coagulation tests
- Oritavancin may atificially prolong aPTT for up to 120 hours, activated clotting time (ACT) for up to 24 hours, and elevate D-dimer concentrations up to 72 hours; use a non-phospholipid dependent coagulation test (Factor Xa chromogenic assay) or an alternative anticoagulant not requiring aPTT monitoring for patients requiring aPTT monitoring within 120 hours of oritavancin dosing
- If acute hypersensitivity reactions occur during infusion, discontinue treatment immediately and institute supportive care. Monitor patients with history of glycopeptide (dalbavancin, telavancin, vancomycin) allergy for signs of hypersensitivity during infusion
- If infusion-related reactions such as pruritus, urticaria, and/or flushing occur, infusion rate should be slowed down or interrupted
- If Clostridium difficile-associated diarrhea (CDAD) is suspected or confirmed, discontinue antibacterial use not directed against <i>C. difficile</i>; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <i>C. difficile</i>, and surgical evaluation as clinically indicated
- Monitor patients for signs and symptoms of osteomyelitis; institute appropriate alternate antibacterial therapy if osteomyelitis is suspected or diagnosed
- Use oritavancin to treat infections that are proven or strongly suspected to be caused by susceptible bacteria to reduce the development of drug-resistant bacteria and maintain the effectiveness of oritavancin and other antibacterial drugs
Caution: Use cautiously in
- Patients on chronic warfarin therapy
- Patients with hypersensitivity to other glycopeptides (dalbavancin, telavancin, vancomycin)
- Patients with infusion-related reactions
Pregnancy Category:C
Breastfeeding: Safety unknown. Manufacturer advises caution
